1. In Vivo
  2. >>Innovation

Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s

 
• By Maire Gerrard

Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.

Neuron_Cells

Vivoryon Therapeutics is expected to start enrollment for a Phase IIb trial of its lead Alzheimer’s disease treatment in the second quarter of 2020 in Europe, with topline data due in late-2022. Ulrich Dauer, who joined the company as CEO in 2018, spoke to In Vivo during the recent, virtual BIO-Europe Spring conference about the company’s work in Alzheimer’s, how they are approaching the challenges raised by the coronavirus outbreak and their goals for the remainder of 2020.

Probiodrug changed its name to Vivoryon in June 2019. Dauer said at the time that the new name was “representative of the evolving commitment of the company to promote healthy-aging.”...

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.